Metatron Capital SICAV’s Pfizer PFE Stock Holding History

Metatron Capital SICAV’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$2.28M	Buy	+38,600	New	+$1.91M	2.17%	5

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Metatron Capital SICAV's PFE Position: Q4 2021 in Review

Metatron Capital SICAV opened a new position in Pfizer (PFE) in Q4 2021: 38,600 shares worth $2.28M. The stake represents 2.17% of the portfolio and ranks #5 among its holdings.

3,262 funds tracked by Wall St. Rank hold PFE as of Q4 2021.

Metatron Capital SICAV held 38,600 shares of Pfizer worth $2.28M as of Q4 2021.
Pfizer was a new Metatron Capital SICAV position in Q4 2021.
Pfizer made up 2.17% of Metatron Capital SICAV's portfolio in Q4 2021, its #5 holding.
3,262 funds tracked by Wall St. Rank held Pfizer as of Q4 2021.

Based on Metatron Capital SICAV's 13F filing for Q4 2021, filed 15 Feb 2022.